5mC antibody and nucleic acid modification reagents: detecting a mark, not a protein

Using a modification reagent

1. Make the mark accessible. Marks on double stranded nucleic acid are not available to an antibody until the template is denatured, and marks on folded proteins may need digestion or unfolding. The accessibility step is the method, and skipping it produces a clean negative.
2. Prove specificity against the unmodified template. Run a sample known to lack the modification and, where possible, a synthetic template carrying and lacking it. Without that pair the signal cannot be attributed to the mark.
3. Enrich before detecting where the mark is rare. Most modifications occupy a small fraction of their substrate. Immunoprecipitation with the modification reagent followed by detection of the substrate is frequently the only way to see it.
4. Expect a smear and quantify it as one. A mark present across many proteins or many sites gives a distribution. Integrating a region, with a defined region and a matched control lane, is the honest quantification.
5. Block the erasers at collection. Enzymes that remove these marks stay active in a lysate. Their inhibitors have to be in the buffer before the sample meets it, exactly as for phosphorylation.

Reagents for RNA marks are the least reliable

Antibodies against RNA modifications have a documented history of variable specificity between clones and lots, and several published patterns have not reproduced with orthogonal methods. That is a reason for caution rather than avoidance.

Where a conclusion rests on an RNA modification, confirm with an antibody independent method. Enzymatic or sequencing based approaches exist for the common marks and settle the question.

Global marks and local claims

A modification reagent reports the total across the sample. Claiming that a specific protein or a specific locus carries the mark requires enrichment followed by identification, not a global blot with an arrow.

State what was measured. Global change is a real and interesting observation; it is simply a different claim from site specific modification.

An 8 ohdg antibody and the lesion it reports

Oxidised guanine is a damage marker rather than a regulatory mark, so an 8 ohdg antibody answers a different question from a methylation antibody even though both read a modified base. Signal depends on how the DNA was prepared, since extraction itself oxidises guanine, and a sample handled slowly reads high for a reason that has nothing to do with the biology. A processing matched control is the only usable comparison.

An ogg1 antibody on the glycosylase that removes the lesion

The repair enzyme that excises oxidised guanine is read for expression and localisation rather than for activity, and an ogg1 antibody is therefore usually a blot and a fractionation reagent. Because the protein is present at modest levels, a positive control lysate and an overexpression lane are what make a faint band believable. Activity belongs to a cleavage assay, and no antibody substitutes for that measurement.

A tet1 antibody and the demethylation intermediates

The TET enzymes oxidise methylated cytosine through hydroxymethyl and formyl intermediates, so a tet1 antibody is bought alongside antibodies against those bases rather than instead of them. The protein is very large, which makes transfer the usual failure, and the family shares domains, which makes the immunogen and the knockout validation the two things worth reading on the datasheet before anything is ordered.

An lsd1 antibody and complex dependent epitopes

This demethylase works inside larger corepressor complexes, and clones differ in whether they reach their epitope while the complex is assembled. That decides whether the antibody is useful for immunoprecipitation or only for a denatured blot. An lsd1 antibody used for chromatin work needs data from that application specifically, since a clean western blot says nothing about crosslinked chromatin.

A setdb1 antibody beside the mark it writes

An enzyme antibody and a mark antibody answer different questions, and the pair is what makes an argument: a setdb1 antibody shows the writer is present, while an antibody against trimethylated H3K9 shows the mark was made. Where a knockdown is the experiment, both readouts belong in the figure, because a loss of enzyme with no loss of mark is a real and informative result rather than a failure.

A sirt6 antibody and the fraction it is read in

Chromatin associated proteins are lost by a whole cell lysate that never solubilised the nucleus, so a sirt6 antibody is read on a fractionation with the fractions marked: a cytoplasmic protein, a nuclear soluble protein and a histone in their own lanes. Without those markers a faint band cannot be told from a preparation that failed. The same fractionation is what makes a translocation claim measurable.

A suv39h1 antibody and its paralogue

SUV39H1 and SUV39H2 are close enough that a clone raised against a conserved region reports both, and in a tissue where only one is expressed that distinction changes the conclusion. A suv39h1 antibody should carry cross reactivity data against the paralogue, and the cleanest validation is a knockout lysate. Expected mass and the species tested are the other two lines worth reading before ordering.

A dnmt1 antibody across the cell cycle

The maintenance methyltransferase is cell cycle regulated and concentrates at replication foci, so a dnmt1 antibody reads differently in a confluent culture and in a dividing one, and a comparison needs the proliferation state stated. The protein is large, so transfer conditions matter, and the replication focus pattern in S phase cells is the internal evidence that the stain is real rather than nuclear background.

Common questions

Why does my modification stain show nothing?

Usually accessibility. Marks on double stranded nucleic acid need denaturation, and buried protein marks need digestion or unfolding. Add the step before changing reagents.

How is specificity of a 5mC antibody demonstrated?

With a template known to carry the mark and one known to lack it, run side by side, plus a competition with free modified substrate where available. A supplier's dot blot is a starting point, not evidence in your system.

Can these reagents be quantitative?

Relatively, within one experiment with matched controls and a defined integration region. Absolute quantification of a modification by antibody is not reliable, and mass spectrometry is the method when a number is needed.

Browse by service class

• Compare Gene synthesis on advertised prices